SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales moved down -36.99% to Rs. 2487.30 millions for the December 2023 quarter as compared to Rs. 3947.50 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2023 is Rs. -2753.30 millions as compared to Net Profit of Rs. 4.20 millions of corresponding quarter ended December 2022Operating profit Margin for the quarter ended December 2023 slipped to -1612.30% as compared to 520.60% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 2487.30 3947.50 -36.99 10262.80 10631.90 -3.47 14438.10 12683.40 13.83
Other Income 4.40 67.70 -93.50 37.40 170.20 -78.03 221.40 187.60 18.02
PBIDT -1612.30 520.60 -409.70 -1011.20 995.10 -201.62 1561.80 991.10 57.58
Interest 253.70 236.40 7.32 753.50 681.00 10.65 900.60 752.70 19.65
PBDT -2493.70 284.20 -977.45 -2427.90 314.10 -872.97 661.20 203.50 224.91
Depreciation 259.60 278.90 -6.92 779.30 845.00 -7.78 1109.00 1120.10 -0.99
PBT -2753.30 5.30 -52049.06 -3207.20 -530.90 504.11 -447.80 -916.60 -51.15
TAX 0.00 1.10 0.00 -102.50 -244.20 -58.03 -225.70 -331.00 -31.81
Deferred Tax 0.00 2.20 0.00 -102.50 -243.10 -57.84 -224.60 -331.00 -32.15
PAT -2753.30 4.20 -65654.76 -3104.70 -286.70 982.91 -222.10 -585.60 -62.07
Equity 360.00 360.00 0.00 360.00 360.00 0.00 360.00 360.00 0.00
PBIDTM(%) -64.82 13.19 -591.51 -9.85 9.36 -205.27 10.82 7.81 38.43

Solara Active Pharma Share Price

491.95 -7.30 (-1.46%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×